Spruce Point Capital, a forensic short seller, says IperionX (Nasdaq: IPX) appears to have sharply restated how much titanium powder it made in the June quarter. The company's new quarterly report lists 1.4 tons for June and 8.7 tons for September, with inventory building while it moves from testing to orders. We could not confirm the restatement claim. The stock rose 9.3% to $17.04 on October 29, 2026, the day of the report, then fell 12.6% to $14.89 by the November 3 close.
This is journalism and commentary, not investment advice. We hold no position unless stated.
Key facts
- Ticker: IPX, listed on Nasdaq and the ASX; based in Virginia.
- Price: $14.89 at the November 3, 2026 close, down 12.6% from $17.04 on October 29, when the shares rose 9.3% from $15.59 on the day of the report.
- Production: 8.7 tons of titanium powder in the September quarter versus 1.4 tons in the June quarter, per the quarterly report.
- Inventory: 19 tons of finished powder and 207 tons of titanium scrap feedstock at September 30.
- Cash: $63.0 million at September 30, up from $35.2 million after a $50 million share offering in July; net operating cash outflow of $12.6 million in the quarter.
- Next-generation process: a continuous GenX platform validated at an equivalent run-rate of about 100 tons a year, per the same report.
- Government work: an $18.5 million Army task order, with $79.2 million left under a $99 million contract ceiling.
- The short: Spruce Point published its IperionX report in November 2025 and has repeated the call since.
Is IPX a good bet right now?
It depends on whether IperionX turns pilot output into steady revenue. The new report shows production rising and a stronger balance sheet, but most of the business is still funded by share sales and government awards. Spruce's new point is about reporting quality. If it is right, that matters more than any single quarter. If it is wrong, the claim adds little to the existing short case.
Why are short sellers bearish on IperionX?
On October 29 Spruce wrote that a monthly production chart IperionX showed earlier implied more than 4 tons in the June quarter, not 1.4 tons. Its conclusion: "If the production is wrong, then there's a high likelihood the financial results are wrong too."
- Inventory build. Spruce says inventory is piling up while commercial sales are still absent.
- Earlier doubts. On October 21 Spruce questioned the company's consumer electronics pitch.
- Audit call. On October 29 Spruce said taxpayers should ask the Government Accountability Office to audit IperionX and the government programs it works on, citing the past restatement and the powder reporting questions.
- Past restatement. Spruce says IperionX already did one restatement that shareholders revolted on. We could not verify that claim, and we have not seen the earlier chart.
Who's making this call and why?
Spruce Point Capital Management, founded by Ben Axler, publishes forensic short reports. Its original IperionX report argued for 70% to 95% downside under some scenarios.
Track record. In our tracking, Spruce Point is 11-6 (a .647 win rate) on 17 calls scored at 180 days against the S&P 500, ranked 3rd on the career board, with an average edge of +10.4 points. All 17 are shorts, and its last 10 went 6-4. Its November 2025 IperionX short counted as a miss at 180 days, when the stock was up about 10%. The shares have since fallen about 60% from $37.47 to $14.89 at the November 3 close. Its October 29 reiteration, made at $15.59, is provisional and leads the index by about 2 points through November 3. See the scoreboard and our earlier IPX piece.
Who disagrees?
We found no detailed bull rebuttal on X. The case against Spruce comes from the company and the tape.
- Output is rising. IperionX says its HAMR furnace ran 1.6 tons in 63 hours and validated capacity above 200 tons a year.
- Early orders. It finished parts under a Carver Pump order for Navy pump work and won a follow-on Army order for vehicle fasteners. It also made 1,500 fasteners.
- Insider buying. Directors bought about $1.9 million of shares on the market in July.
- The market. Shares rose 9.3% on the day of the report but gave back that gain and more by November 3.
What are the key facts to verify?
- The quarterly report for production, inventory and cash.
- Earlier IperionX presentations for the monthly production chart Spruce cites.
- Whether any past financial statements were actually restated, and how shareholders voted.
- The November 25, 2026 annual meeting, and the shareholder approval the planned move to a Texas parent requires.
What would prove it right or wrong?
Right: IperionX corrects past production or financial figures, inventory keeps rising without matching sales, or it needs another large share sale.
Wrong: the June figure is explained, recurring commercial orders arrive and revenue starts to track output.
This is journalism and commentary, not investment advice. We hold no position unless stated.
